Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Leukemia Group Backs Onconova Treatment

by Marc S. Reisch
June 7, 2010 | A version of this story appeared in Volume 88, Issue 23

Onconova Therapeutics and the Leukemia & Lymphoma Society have partnered to push Estybon, Onconova’s myelodysplastic syndrome treatment, toward commercialization. LLS will provide up to $10 million in funding for what the partners call an “approval track” clinical trial in patients with the blood disease. This is the first time the nonprofit is funding a trial of this scale under its Therapy Acceleration Program, a vehicle established in 2007 to support for-profit enterprises that advance leukemia and lymphoma treatments.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.